These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 991901)

  • 21. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
    Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
    Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
    [No Abstract]   [Full Text] [Related]  

  • 23. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.
    Yalowich JC; Ross WE
    Cancer Res; 1984 Aug; 44(8):3360-5. PubMed ID: 6744270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection and characterization of L1210 sublines resistant to teniposide (VM-26).
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2981-5. PubMed ID: 6722821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.
    Rowe T; Kupfer G; Ross W
    Biochem Pharmacol; 1985 Jul; 34(14):2483-7. PubMed ID: 2990488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.
    Lee T; Roberts D
    Cancer Res; 1984 Jul; 44(7):2986-90. PubMed ID: 6722822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs.
    Roberts D; Hilliard S; Peck C
    Cancer Res; 1980 Nov; 40(11):4225-31. PubMed ID: 7471063
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.
    Hacker M; Roberts D; Jackson CW
    Br J Cancer; 1980 Nov; 42(5):697-702. PubMed ID: 7459207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a water-soluble and a water-insoluble podophyllotoxin derivative in murine neoplasms.
    Kreis W; Soricelli A
    J Cancer Res Clin Oncol; 1979; 95(3):233-7. PubMed ID: 528564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological activity of galactopyranoside derivatives of 4'-demethylepipodophyllotoxin showing VP-16 (etoposide)-like activity.
    Pamidi CC; Derry WB; Gupta RS
    Anticancer Drug Des; 1991 Nov; 6(5):481-93. PubMed ID: 1764166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Mathé G; Schwarzenberg L; Pouillart P; Oldham R; Weiner R; Jasmin C; Rosenfeld C; Hayat M; Misset JL; Musset M; Schneider M; Amiel JL; De Vassal F
    Cancer; 1974 Oct; 34(4):985-92. PubMed ID: 4608026
    [No Abstract]   [Full Text] [Related]  

  • 34. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
    [No Abstract]   [Full Text] [Related]  

  • 35. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
    White JC; Hines LH; Rathmell JP
    Cancer Res; 1985 Jul; 45(7):3070-5. PubMed ID: 4005845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer drugs. II. Synthesis and biological evaluation of spin labeled derivatives of podophyllotoxin.
    Chen YZ; Wang YG; Li JX; Tian X; Jia ZP; Zhang PY
    Life Sci; 1989; 45(26):2569-75. PubMed ID: 2615556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.
    Loike JD; Brewer CF; Sternlicht H; Gensler WJ; Horwitz SB
    Cancer Res; 1978 Sep; 38(9):2688-93. PubMed ID: 679171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.
    Roberts D; Lee T; Parganas E; Wiggins L; Yalowich J; Ashmun R
    Cancer Chemother Pharmacol; 1987; 19(2):123-30. PubMed ID: 3568269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.